Skip to main content
Clinical Trials/JPRN-jRCT1061230099
JPRN-jRCT1061230099
Recruiting
Phase 4

comparison of short term efficacy of pain and QOL between romosozumab and risedronate against osteoporotic vertebral fractures

Tetsunaga Tomoko0 sites60 target enrollmentFebruary 7, 2024

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Tetsunaga Tomoko
Enrollment
60
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 7, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Tetsunaga Tomoko

Eligibility Criteria

Inclusion Criteria

  • 1\)Patients with vertebral fracture with vertebral body compression on X\-ray and with vertebral body signal sntensity change on MRI.
  • 2\)Patients with osteoporosis with high risk of oste oporotic fractures.
  • 3\)Patients with more than 5 score of NRS(Numerical Rating Scale) at first visiting
  • 4\)Patients aged 50 years or older at the time of consect acquisition.
  • 5\)Patients who received sufficient explanation before participating in this study, and obtained the patient's free will to consent to the document after sufficient understanding.
  • 6\)Inpatients and outpatients

Exclusion Criteria

  • 1\)Patients under treatment for osteoporosis at the time of injury.
  • 2\)Patients due to high energy trauma.
  • 3\)patients with severe kidney disease(eGFR\<30\).
  • 4\)Patients with hypocalcemia
  • 5\)Patients who cannot answer the questionnaire due to dementia
  • 6\)Patients who need invasive dental treatment
  • 7\)Patients who are judged by the principal investigator and the research coordinator to be
  • inappropriate as research subjects

Outcomes

Primary Outcomes

Not specified

Similar Trials